By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


SEARCH JOBS

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.

YEAR FOUNDED:

1980

LEADERSHIP:

CEO: Ed Kaye, M.D.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: avi@avibio.com
Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT
 



Industry
Biotechnology






Company News
Sarepta (SRPT) Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping 9/29/2016 10:27:15 AM
Catabasis (CATB) And Sarepta (SRPT) Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy 9/29/2016 9:27:16 AM
Sarepta (SRPT) Announces Pricing Of $300 Million Public Offering Of Common Stock 9/23/2016 9:57:04 AM
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too 9/23/2016 7:40:10 AM
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study 9/23/2016 6:29:16 AM
Sarepta (SRPT) Announces Proposed Public Offering Of Common Stock 9/22/2016 12:07:43 PM
With Its Eyes on the DMD Drug Prize, Sarepta (SRPT) to Raise $225 Million in Stock Sale 9/22/2016 6:12:15 AM
Sarepta (SRPT) Announces Favorable USPTO Decisions In Exon 51 And Exon 53 Composition Of Matter Patent Interference Cases Against BioMarin (BMRN) 9/21/2016 9:25:45 AM
Sarepta (SRPT) Announces FDA Accelerated Approval Of EXONDYS 51 (Eteplirsen) Injection, An Exon Skipping Therapy To Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable To Skipping Exon 51 9/21/2016 8:51:27 AM
The Power of Three: Sarepta (SRPT) to Open New Plant, Hire Staff and Confirms Kaye as CEO 9/21/2016 7:03:45 AM
12345678910...
//-->